Wellbeing
Most PCS patients still ill in year two
Metadata + PaperFren explanation · cc by · source: Europe PMC
In a German nested case-control follow-up, 67.6% of PCS cases remained symptomatic at phase 2 while 78.5% of recovered controls stayed well; symptoms stayed nonspecific without lab evidence of viral persistence.
Study at a glance
- Design
- Case-control — Nested phase-2 outpatient assessment of PCS cases vs age/sex-matched recovered controls
- N
- N=1558 · 982 PCS cases and 576 matched recovered controls; median 8.5 months after phase 1
- Population
- Adults 18–65 with prior questionnaire-defined PCS or recovery in southwestern Germany
- Outcome
- Persistence of PCS symptoms and associated clinical/lab profiles
Structured fields used in claim comparison tables when every cited study has a complete layer.
Key findings
At phase 2, 67.6% of phase-1 PCS patients had persistent PCS; 78.5% of phase-1 recovered participants stayed free of PCS-related problems. Persistent cases were less often never smokers (61.2% vs 75.7%) and more often obese (30.2% vs 12.4%). Symptom patterns stayed dominated by fatigue, exercise intolerance, and cognitive complaints; labs did not support viral persistence, EBV reactivation, adrenal insufficiency, or increased complement turnover.
Methodology
Nested case-control follow-up (phase 2) of adults aged 18–65 from an earlier population questionnaire study: 982 PCS cases and 576 age- and sex-matched recovered controls underwent comprehensive outpatient assessment (neurocognitive, cardiopulmonary exercise, laboratory testing) at four university centres in southwestern Germany, a median 8.5 months after phase 1.
Limitations
Volunteers may differ from non-participants; controls were symptom-free at phase 1, not uninfected comparators. Objective deficits do not pinpoint a single mechanism, and findings may not generalize beyond working-age southwestern Germany.
How this study connects
Role on claims
Each row is a claim on a concept or method page where this paper supports, challenges, or qualifies the statement. Roles are hand-checked — not a model guess.
In post-COVID clinics, simple reaction time can be severely slowed versus controls.
In NICE-defined post-COVID clinic samples, simple reaction time can be severely slowed (~3 SD vs controls), with more than half of patients past a >2 SD threshold, and the slowing replicates across UK and German sites. That supports a position that some people with PCC have large, objective psychomotor slowing—not only self-reported fog.
Scope note — different outcome — persistent symptoms, not SRT slowing
Limits the claim's scope: a different population, assay, or outcome.
Cognitive complaints can remain part of lasting post-COVID syndrome into the second year.
Among adults still meeting post-COVID syndrome criteria into the second year after infection, cognitive complaints remain part of a durable symptom pattern dominated by fatigue and exercise intolerance; most previously recovered controls stay well.
Evidence for the claim as stated.
EHR “long COVID” codes cluster diagnoses but skew toward more advantaged patients.
US EHR coding with ICD-10-CM U09.9 clusters co-occurring diagnoses into organ-system themes, but coded patients skew toward more advantaged demographics relative to acute COVID burden.
Scope note — different population — nested PCS follow-up, not EHR-coded
Limits the claim's scope: a different population, assay, or outcome.
NICE clinic PCC, nested questionnaire PCS with outpatient workups, and U09.9 EHR codes are different case definitions with different selection biases. Large objective slowing in specialty clinics need not describe every coded or community PCS case—this is a scope limit, not evidence that one study’s slowing estimate is wrong.
Evidence for the claim as stated.
Year-two outpatient assessments found persistent symptoms without lab support for viral persistence, EBV reactivation, adrenal failure, or increased complement turnover. Durable cognitive complaints therefore do not, in that cohort, pin a single blood-testable mechanism—an open mechanistic limit rather than a conflict with the SRT slowing finding.
Evidence for the claim as stated.
Open questions
Tensions this paper is part of
From concept pages' “where studies disagree.” Disagreement means the same question; scope means different assays, populations, or outcomes.
NICE clinic PCC, nested questionnaire PCS with outpatient workups, and U09.9 EHR codes are different case definitions with different selection biases. Large objective slowing in specialty clinics need not describe every coded or community PCS case—this is a scope limit, not evidence that one study’s slowing estimate is wrong.
Year-two outpatient assessments found persistent symptoms without lab support for viral persistence, EBV reactivation, adrenal failure, or increased complement turnover. Durable cognitive complaints therefore do not, in that cohort, pin a single blood-testable mechanism—an open mechanistic limit rather than a conflict with the SRT slowing finding.
Related papers in this topic
Same topic cluster — not a recommendation engine.